Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homobarringtonie is a natural alkaloid that belongs to the cephalotaxine class, structurally related to homoharringtonine and omacetaxine mepesuccinate. It acts primarily as a protein synthesis inhibitor, binding to ribosomes and interfering with elongation of nascent peptide chains, which leads to inhibition of protein synthesis, induction of apoptosis, and cell cycle arrest in tumor cells. Homobarringtonie has been studied for efficacy in the treatment of hematological malignancies, particularly acute myeloid leukemia (AML) and other myeloid cancers, often in combination regimens. It is noted for cytotoxic and antitumor activities and appears to share mechanisms with homoharringtonine, but is referenced as a distinct entity in therapeutic combinations in recent clinical research[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on homobarringtonie.